Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Myelodysplastic Syndrome (MDS) Drugs Market

Myelodysplastic Syndrome (MDS) Drugs Market Size

  • Report ID: GMI10852
  • Published Date: Aug 2024
  • Report Format: PDF

Myelodysplastic Syndrome Drugs Market Size

Myelodysplastic Syndrome Drugs Market size was valued at USD 2.8 billion in 2023 and is estimated to grow at 8% CAGR from 2024 to 2032. The market is experiencing dynamic growth driven by the increasing incidence of MDS, particularly among the aging population, this has risen the demand for effective treatments.

 

For instance, according to the American Cancer Society, approximately 10,000 new cases of MDS are diagnosed annually in the U.S. alone, with a higher incidence in individuals over 60 years old. As a result, the adoption of myelodysplastic syndrome (MDS) drugs is increasing. Moreover, the rise in technological advancement in diagnostic techniques have improved early detection of MDS, which can lead to earlier and more effective treatment, thus increasing the demand for MDS drugs. Furthermore, strategic collaborations and partnerships among biotech firms and research institutions are accelerating the development of new therapies, thereby contributing the market growth.

 

MDS drugs refer to the pharmaceutical treatments used to manage and treat myelodysplastic syndromes (MDS), which are a group of disorders caused by poorly formed or dysfunctional blood cells. MDS affects the bone marrow's ability to produce healthy blood cells, leading to problems like anemia, infections, and bleeding. This market includes a wide range of therapeutic agents such as hypomethylating agents, immunomodulatory drugs, anti-anemics drugs etc.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Myelodysplastic syndrome drugs market size was USD 2.8 billion in 2023 and is expected to register 8% CAGR from 2024-2032 owing to increasing incidence of MDS, particularly among the aging population worldwide.

Myelodysplastic syndrome drugs industry from the hypomethylating drugs segment reached USD 1.5 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to their ability to improve survival rates.

North America myelodysplastic syndrome drugs industry reached USD 1.2 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to a high prevalence of disease, advanced healthcare infrastructure, and significant healthcare expenditure in the region.

Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd, are some of the major myelodysplastic syndrome (MDS) drugs companies worldwide.

Myelodysplastic Syndrome Drugs Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 518
  • Countries covered: 23
  • Pages: 300
 Download Free Sample